Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study

Antonella Di Cesare; Elia Rosi; Emanuele Trovato; Leonardo Pescitelli; Salvatore Panduri; Flavia Manzo Margiotta; Alessandra Michelucci; Eugenio Capalbo; Martina Dragotto; Michela  Magnano; Susanna Rossari; Imma Savarese; Gionata Buggiani; Nicola Milanesi; Elisa Lorenzoni; Federica Ricceri; Marco Romanelli; Pietro Rubegni; Nicola Pimpinelli; Francesca Prignano

doi:10.5826/dpc.1504a5733

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study

Authors

Antonella Di Cesare Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
Elia Rosi Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
Emanuele Trovato Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
Leonardo Pescitelli Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy
Salvatore Panduri Department of Dermatology, University of Pisa, Pisa, Italy
Flavia Manzo Margiotta Department of Dermatology, University of Pisa, Pisa, Italy
Alessandra Michelucci Department of Dermatology, University of Pisa, Pisa, Italy
Eugenio Capalbo Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
Martina Dragotto Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
Michela Magnano Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
Susanna Rossari Unit of Dermatology, Versilia Hospital, Lido di Camaiore, Lucca, Italy
Imma Savarese Department of Dermatology, San Jacopo Hospital, Pistoia, Italy
Gionata Buggiani Unit of Dermatology, San Giuseppe Hospital, Empoli, Florence, Italy
Nicola Milanesi Department of Dermatology, San Jacopo Hospital, Pistoia, Italy
Elisa Lorenzoni Unit of Dermatology, Hospital of Campo di Marte, Lucca, Italy
Federica Ricceri Unit of Dermatology, San Donato Hospital, Arezzo, Italy
Marco Romanelli Department of Dermatology, University of Pisa, Pisa, Italy
Pietro Rubegni Dermatology Section, Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
Nicola Pimpinelli Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy
Francesca Prignano Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy

Keywords:

psoriasis, SII, risankizumab, SIRI, NLR

Abstract

Introduction: Whole blood cells and derived indices can be used as a read-out of the inflammatory pathogenic processes in many human diseases, including psoriasis. Indeed, systemic treatments with special regard to anti-IL-23 agents could exert anti-inflammatory and disease modifying effects; however, there is still a lack of conclusive data.

Objectives: We aimed to assess the therapeutic effect of risankizumab on whole blood cells and inflammatory indices in psoriatic patients.

Methods: We performed a prospective multicenter observational study on adult patients with moderate-to-severe psoriasis who underwent risankizumab therapy for at least 52 weeks. Blood cell count, CRP, and ESR were prospectively recorded for each patient included in the study, at routine visits up to week 52. The ratio between peripheral cells, namely NLR, PLR, MLR, SII, and PIV, were calculated and compared at time 0 and at weeks 12, 24, and 52 of treatment. At different timepoints, modulation of laboratory values and derived indices and their correlation with disease severity and response to treatment were analyzed. Subanalysis of very early responders and late responders was performed as well.

Results: We observed a progressive reduction in inflammatory indices such as CRP, ESR, NLR, and SII during treatment, with prominent modification involving SIRI as well, in patients who had a very early and almost complete response to risankizumab. Reduction in neutrophils and MPV, a transient increase in eosinophils at week 12, and a progressive increase in peripheral basophils were associated with therapeutic response.

Conclusion: Risankizumab promotes a progressive anti-inflammatory effect, more prominent in patients with a faster response in the early phases of treatment.

References

Guo L, Huang Y, He J, Li D, Li W, Xiao H, Xu X, Zhang Y, Wang R. Associations of lifestyle characteristics with circulating immune markers in the general population based on NHANES 1999 to 2014. Sci Rep. 2024 Jun 11;14(1):13444. doi: 10.1038/s41598-024-63875-2. PMID: 38862546.

Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. Int J Mol Sci. 2022 Mar 26;23(7):3636. doi: 10.3390/ijms23073636. PMID: 35408994.

Islam MM, Satici MO, Eroglu SE. Unraveling the clinical significance and prognostic value of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and delta neutrophil index: An extensive literature review. Turk J Emerg Med. 2024 Jan 8;24(1):8-19. doi: 10.4103/tjem.tjem_198_23. PMID: 38343523.

Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474-488. doi: 10.4149/BLL_2021_078. PMID: 34161115.

Gambichler T, Hessam S, Cramer P, Abu Rached N, Bechara FG. Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1593-1596. doi: 10.1111/jdv.18175. Epub 2022 May 7. PMID: 35462426.

Li W, Wang X, Diao H, Yang Y, Ding L, Huan W, Chen Y, Cui W. Systemic immune inflammation index with all-cause and cause-specific mortality: a meta-analysis. Inflamm Res. 2024 Dec;73(12):2199-2216. doi: 10.1007/s00011-024-01959-5. Epub 2024 Oct 14. PMID: 39400697.

Pang J, Ding N, Yin N, Xiao Z. Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy. Sci Rep. 2024 Mar 19;14(1):6578. doi: 10.1038/s41598-024-57343-0. PMID: 38503890.

Deng X, Liu D, Li M, He J, Fu Y. Association between systemic immune-inflammation index and insulin resistance and mortality. Sci Rep. 2024 Jan 23;14(1):2013. doi: 10.1038/s41598-024-51878-y. PMID: 38263234.

Pérez-Martelo M, González-García A, Vidal-Ínsua Y, Blanco-Freire C, Brozos-Vázquez EM, Abdulkader-Nallib I, Álvarez-Fernández J, Lázare-Iglesias H, García-Martínez C, Betancor YZ, Sánchez-Ares M, Tubío JMC, Vázquez-Rivera F, Candamio-Folgar S, López-López R, Ruiz-Bañobre J. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy. Sci Rep. 2022 Apr 27;12(1):6893. doi: 10.1038/s41598-022-10884-8. PMID: 35477740.

Fucà G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L, Sartore-Bianchi A, Borelli B, Tampellini M, Bustreo S, Claravezza M, Boccaccino A, Murialdo R, Zaniboni A, Tomasello G, Loupakis F, Adamo V, Tonini G, Cortesi E, de Braud F, Cremolini C, Pietrantonio F. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19. PMID: 3242414811. Ye JH, Zhang Y, Naidoo K, Ye S. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in psoriasis: a systematic review and meta-analysis. Arch Dermatol Res. 2024 Feb 8;316(3):85. doi: 10.1007/s00403-024-02823-6. PMID: 38329632.

Liu YC, Chuang SH, Chen YP, Shih YH. Associations of novel complete blood count-derived inflammatory markers with psoriasis: a systematic review and meta-analysis. Arch Dermatol Res. 2024 May 24;316(6):228. doi: 10.1007/s00403-024-02994-2. PMID: 38787437.

Morariu SH, Cotoi OS, Tiucă OM, Baican A, Gheucă-Solovăstru L, Decean H, Brihan I, Silaghi K, Biro V, Șerban-Pescar D, Măgureanu I, Ambros M, Ilcuș RI, Prodan L, Bălan AB, Husariu M, Gugulus DL, Stan RA, Voiculescu V, Nicolescu AC. Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study. J Clin Med. 2024 Jul 9;13(14):3992. doi: 10.3390/jcm13143992. PMID: 39064032; PMCID: PMC11277525.

Kulakli S, Oguz ID, Aksan B. Could Blood Cell-Based Inflammatory Markers Be Used to Monitor Response to Biologic Therapy in Psoriasis? Sisli Etfal Hastan Tip Bul. 2023 Dec 20;57(4):536-542. doi: 10.14744/SEMB.2023.43569. PMID: 3826865515. Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2021 Oct 21;9(11):1511. doi: 10.3390/biomedicines9111511. PMID: 34829740; PMCID: PMC8615182.

Man AM, Orăsan MS, Hoteiuc OA, Olănescu-Vaida-Voevod MC, Mocan T. Inflammation and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2023 Nov 8;24(22):16095. doi: 10.3390/ijms242216095. PMID: 38003284.

Visser MJE, Venter C, Roberts TJ, Tarr G, Pretorius E. Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function. Sci Rep. 2021 Jun 22;11(1):13043. doi: 10.1038/s41598-021-90684-8. PMID: 3415853718. Jin M, Yuan S, Yuan Y, Yi L. Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis. Front Oncol. 2021 Dec 7;11:735803. doi: 10.3389/fonc.2021.735803. PMID: 34950577.

Cai Y, Zhao L, Zhang Y, Luo D. Association between blood inflammatory indicators and prognosis of papillary thyroid carcinoma: a narrative review. Gland Surg. 2024 Jun 30;13(6):1088-1096. doi: 10.21037/gs-24-72. Epub 2024 Jun 25. PMID: 39015725.

Han X, Liu S, Yang G, Hosseinifard H, Imani S, Yang L, Maghsoudloo M, Fu S, Wen Q, Liu Q. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies. Gynecol Oncol. 2021 Jan;160(1):351-360. doi: 10.1016/j.ygyno.2020.10.011. Epub 2020 Oct 19. PMID: 33092868.

Chen X, Li A, Ma Q. Neutrophil-lymphocyte ratio and systemic immune-inflammation index as predictors of cardiovascular risk and mortality in prediabetes and diabetes: a population-based study. Inflammopharmacology. 2024 Oct;32(5):3213-3227. doi: 10.1007/s10787-024-01559-z. Epub 2024 Aug 21. PMID: 39167310.

Aon M, Aoun AH, Alshami A, Alharbi A, Alshammari F, Alnajjar M, Almutawtah A, Bin Naji B, Alsaeed A, Abdelwahab OA. Association of the systemic immune-inflammation index (SII) and severity of diabetic ketoacidosis in patients with type 1 diabetes mellitus: a retrospective cohort study. Ann Med Surg (Lond). 2024 May 20;86(7):3865-3872. doi: 10.1097/MS9.0000000000002185. PMID: 3898921.

Yorulmaz A, Hayran Y, Akpinar U, Yalcin B. Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis. Curr Health Sci J. 2020 Oct-Dec;46(4):352-357. doi: 10.12865/CHSJ.46.04.05. Epub 2020 Dec 31. PMID: 33717509.

Kim DS, Shin D, Lee MS, Kim HJ, Kim DY, Kim SM, Lee MG. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016 Mar;43(3):305-10. doi: 10.1111/1346-8138.13061. Epub 2015 Aug 18. PMID: 26381893.

Tiucă OM, Morariu SH, Mariean CR, Tiucă RA, Nicolescu AC, Cotoi OS. Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression. Life (Basel). 2024 Jan 12;14(1):114. doi: 10.3390/life14010114. PMID: 38255729.

Joseph J, Truong K, Lo SN, Foo F, Zaman S, Chow CK, Smith A. Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort-a Retrospective Review. Dermatol Ther (Heidelb). 2024 May;14(5):1337-1348. doi: 10.1007/s13555-024-01154-8. Epub 2024 Apr 25. PMID: 38664362.

Li J, Wang X, Jia W, Wang K, Wang W, Diao W, Ou F, Ma J, Yang Y. Association of the systemic immuno-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with diabetic microvascular complications. Front Endocrinol (Lausanne). 2024 Apr 10;15:1367376. doi: 10.3389/fendo.2024.1367376. PMID: 38660516.

Wang P, Guo X, Zhou Y, Li Z, Yu S, Sun Y, Hua Y. Monocyte-to-high-density lipoprotein ratio and systemic inflammation response index are associated with the risk of metabolic disorders and cardiovascular diseases in general rural population. Front Endocrinol (Lausanne). 2022 Sep 9;13:944991. doi: 10.3389/fendo.2022.944991. PMID: 36157453.

Meng X, Sun H, Tu X, Li W. The Predictive Role of Hematological Parameters in Hypertension. Angiology. 2024 Sep;75(8):705-716. doi: 10.1177/00033197231190423. Epub 2023 Jul 17. PMID: 37459606.

Aljuraiban GS, Gibson R, Oude Griep LM. Associations of Systematic Inflammatory Markers with Diet Quality, Blood Pressure, and Obesity in the AIRWAVE Health Monitoring Study. J Inflamm Res. 2024 May 18;17:3129-3141. doi: 10.2147/JIR.S459238. PMID: 38784102.

Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19. PMID: 35305260.

Zhong X, Huang D, Chen R, Yao L, Ma R, Yu Y, Jiang Y, Kong L, Lu J, Li Y, Shi Y. Positive association between insulin resistance and fatty liver disease in psoriasis: evidence from a cross-sectional study. Front Immunol. 2024 Apr 23;15:1388967. doi: 10.3389/fimmu.2024.1388967. PMID: 38715604.

Gordon KB, Blauvelt A, Bachelez H, Coates LC, Van den Bosch FE, Kaplan B, Koetse W, Ashley DG, Lippe R, Sinvhal R, Papp KA. Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials. Dermatol Ther (Heidelb). 2024 Sep;14(9):2523-2538. doi: 10.1007/s13555-024-01238-5. Epub 2024 Aug 17. PMID: 39153059.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. PMID: 30097359.

Strober B, Bachelez H, Crowley J, Elewski BE, Gooderham M, Menter A, Strohal R, Chen MM, Wu T, Zhan T, Photowala H, Armstrong A. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). J Eur Acad Dermatol Venereol. 2024 May;38(5):864-872. doi: 10.1111/jdv.19748. Epub 2024 Jan 5. PMID: 38179809.

Bellinato F, Chiricozzi A, Piaserico S, Targher G, Gisondi P. Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis? Int J Mol Sci. 2022 Oct 25;23(21):12849. doi: 10.3390/ijms232112849. PMID: 36361639.

Zhao Y, Yang XT, Bai YP, Li LF. Association of Complete Blood Cell Count-Derived Inflammatory Biomarkers with Psoriasis and Mortality. Clin Cosmet Investig Dermatol. 2023 Nov 13;16:3267-3278. doi: 10.2147/CCID.S437936. PMID: 38021430.

Albayrak H. Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response to Treatment with Biological Drugs. J Clin Med. 2023 Aug 22;12(17):5452. doi: 10.3390/jcm12175452. PMID: 37685519.

Zhang Y, Qian H, Kuang YH, Wang Y, Chen WQ, Zhu W. Evaluation of the inflammatory parameters as potential biomarkers of systemic inflammation extent and the disease severity in psoriasis patients. Arch Dermatol Res. 2024 May 24;316(6):229. doi: 10.1007/s00403-024-02972-8. PMID: 38787405.

Andersen CSB, Kvist-Hansen A, Siewertsen M, Enevold C, Hansen PR, Kaur-Knudsen D, Zachariae C, Nielsen CH, Loft N, Skov L. Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int J Mol Sci. 2023 Mar 24;24(7):6111. doi: 10.3390/ijms24076111. PMID: 37047086.

Kearney N, Gorecki P, Acciarri L, Buyze J, Akawung A, Merola JF, Kirby B. Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials. Dermatology. 2025;241(3):272-286. doi: 10.1159/000545148. Epub 2025 Apr 10. PMID: 40209685.

Çelik MS, Aktaş H. The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris. Ir J Med Sci. 2025 Aug;194(4):1329-1334. doi: 10.1007/s11845-025-03969-6. Epub 2025 Jun 2. PMID: 40455345.

Demirel Öğüt N, Ayanoğlu MA, Koç Yıldırım S, Erbağcı E, Ünal S, Gökyayla E. Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis? A retrospective cohort study. Arch Dermatol Res. 2025 Jan 13;317(1):232. doi: 10.1007/s00403-024-03768-6. PMID: 39804473.

Kaya K, Gevher Ö. Effect of adalimumab treatment on inflammatory and hematological parameters in patients with Hidradenitis suppurativa. Cutan Ocul Toxicol. 2024 Dec;43(4):253-257. doi: 10.1080/15569527.2024.2387595. Epub 2024 Aug 11. PMID: 39102513.

Holgersen N, Nielsen VW, Rosenø NAL, Thyssen JP, Egeberg A, Nielsen SH, Ring HC, Thomsen SF. Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa. JAAD Int. 2024 Mar 15;15:170-178. doi: 10.1016/j.jdin.2024.03.002. PMID: 38638915.

Öksüm Solak E, Baran Ketencioglu B, Cinar SL, Kartal D, Borlu M. The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa. Int J Dermatol. 2023 Aug;62(8):1076-1081. doi: 10.1111/ijd.16744. Epub 2023 Jun 12. PMID: 37306156.

Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. J Dermatol. 2017 Oct;44(10):1112-1121. doi: 10.1111/1346-8138.13875. Epub 2017 May 11. PMID: 28493493.

Kim DS, Lee J, Kim SH, Kim SM, Lee MG. Mean platelet volume is elevated in patients with psoriasis vulgaris. Yonsei Med J. 2015 May;56(3):712-8. doi: 10.3349/ymj.2015.56.3.712. PMID: 25837177.

Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat. 2022 Mar;33(2):1091-1096. doi: 10.1080/09546634.2020.1801975. Epub 2020 Aug 4. PMID: 32713225.

An I, Ucmak D, Ozturk M. The effect of biological agent treatment on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and C-reactive protein in psoriasis patients. Postepy Dermatol Alergol. 2020 Apr;37(2):202-206. doi: 10.5114/ada.2020.94838. Epub 2020 May 5. PMID: 32489355; PMCID: PMC7262800.

Alexis AF, Gooderham M, Kwatra SG, Amin A, Taylor S, Espaillat R, Rettig T, Wu T, Shi L, Kaldas MI, Dilley DM, Sinvhal R, Nduaka C, Lockshin B. A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis. Dermatol Ther (Heidelb). 2024 Oct;14(10):2877-2887. doi: 10.1007/s13555-024-01268-z. Epub 2024 Oct 2. PMID: 39358667; PMCID: PMC11480268.

Okada Y, Kajiyama K, Ishiguro C, Nonaka T, Komaki T, Kuga W, Komiyama N, Iguchi T, Horiuchi N, Uyama Y. Risk of neutropenia in psoriasis patients prescribed anti-IL-23 antibody in comparison with anti-IL-17 antibody or adalimumab based on real-world data from the MID-NET® in Japan. J Dermatolog Treat. 2024 Dec;35(1):2373826. doi: 10.1080/09546634.2024.2373826. Epub 2024 Jul 4. PMID: 38964751.

Rodriguez-Rosales YA, Langereis JD, Gorris MAJ, van den Reek JMPA, Fasse E, Netea MG, de Vries IJM, Gomez-Muñoz L, van Cranenbroek B, Körber A, Sondermann W, Joosten I, de Jong EMGJ, Koenen HJPM. Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. J Allergy Clin Immunol. 2021 Oct;148(4):1030-1040. doi: 10.1016/j.jaci.2021.02.041. Epub 2021 Mar 19. PMID: 33745888.

Zhang J, Feng Y, Shi D. NETosis of psoriasis: a critical step in amplifying the inflammatory response. Front Immunol. 2024 Aug 1;15:1374934. doi: 10.3389/fimmu.2024.1374934. PMID: 39148738.

Lambert S, Hambro CA, Johnston A, Stuart PE, Tsoi LC, Nair RP, Elder JT. Neutrophil Extracellular Traps Induce Human Th17 Cells: Effect of Psoriasis-Associated TRAF3IP2 Genotype. J Invest Dermatol. 2019 Jun;139(6):1245-1253. doi: 10.1016/j.jid.2018.11.021. Epub 2018 Dec 5. PMID: 30528823.

Hjort G, Schwarz CW, Skov L, Loft N. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis. JAMA Dermatol. 2024 Aug 1;160(8):830-837. doi: 10.1001/jamadermatol.2024.1677. Erratum in: JAMA Dermatol. 2024 Nov 1;160(11):1257. doi: 10.1001/jamadermatol.2024.4301. PMID: 38888917.

Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, Egeberg A, Skov L. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study. Acta Derm Venereol. 2021 Oct 26;101(10):adv00579. doi: 10.2340/actadv.v101.351. PMID: 34642768.

Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C; PSORT Consortium and on behalf of the BADBIR Study Group. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019 May;180(5):1069-1076. doi: 10.1111/bjd.16776. Epub 2018 Aug 28. PMID: 30155885; PMCID: PMC6519065.

Huang D, Zhong X, Jiang Y, Kong L, Ma R, Lu J, Li Y, Shi Y. Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China. Br J Dermatol. 2024 Sep 18;191(4):616-623. doi: 10.1093/bjd/ljae147. PMID: 38634691.

Egeberg A, Conrad C, Gorecki P, Wegner S, Buyze J, Acciarri L, Thaçi D. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials. Dermatol Ther (Heidelb). 2024 Mar;14(3):745-758. doi: 10.1007/s13555-024-01123-1. Epub 2024 Mar 15. PMID: 38485863; PMCID: PMC10965842.

Torres T, Puig L, Vender R, Yeung J, Carrascosa JM, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, Dauden E, Leite L, Valerio J, Del Alcázar-Viladomiu E, Rull EV, Llamas-Velasco M, Pirro F, Messina F, Bruni M, Licata G, Ricceri F, Nidegger A, Hugo J, Mufti A, Daponte AI, Teixeira L, Balato A, Romanelli M, Prignano F, Gkalpakiotis S, Conrad C, Lazaridou E, Rompoti N, Papoutsaki M, Nogueira M, Chiricozzi A. Drug Survival of Interleukin (IL) 17 and IL 23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi country, Multicentric Cohort Study. Am J Clin Dermatol. 2022 Nov;23(6):891-904. doi: 10.1007/s40257-022-00722-y. Epub 2022 Aug 17. PMID: 35976568.

Landgren AJ, Jonsson CA, Bilberg A, Eliasson B, Torres L, Dehlin M, Jacobsson LTH, Gjertsson I, Larsson I, Klingberg E. Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention. Arthritis Res Ther. 2023 Jul 27;25(1):131. doi: 10.1186/s13075-023-03105-8. PMID: 37501212; PMCID: PMC10373368.

Dragotto M, Capalbo E, Cartocci A, Manzo Margiotta F, Michelucci A, Rosi E, Ricceri F, Simoni B, Savarese I, Milanesi N, Rossari S, Magnano M, Romanelli M, Rubegni P, Prignano F, Di Cesare A, Panduri S, Pescitelli L, Trovato E. Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study. J Eur Acad Dermatol Venereol. 2023 Apr 16. doi: 10.1111/jdv.19117. Epub ahead of print. PMID: 37062048.

Ricceri F, Chiricozzi A, Peris K, Prignano F. Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study. Dermatol Ther. 2022 Nov;35(11):e15793. doi: 10.1111/dth.15793. Epub 2022 Sep 9. PMID: 36038527.

Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatol Ther (Heidelb). 2022 Feb;12(2):561-575. doi: 10.1007/s13555-021-00679-6. Epub 2022 Jan 20. PMID: 35050485.